FeesSafety
Pluang+

Abbott launches Ensure Max Protein 3-in-1 with protein, creatine, and HMB for muscle support.

Others
07 Oct 2026, 16:00 WIB
PRNewsWire
View Source
Bullish
Abbott launches Ensure Max Protein 3-in-1 with protein, creatine, and HMB for muscle support.

Abbott has introduced Ensure Max Protein 3-in-1 Muscle Support, a powder combining 30g of protein, 5g of creatine monohydrate, and 3g of calcium HMB to help build, recover, and preserve muscle. This product targets growing consumer interest in muscle health beyond athletic use, offering a convenient, science-backed supplement for strength and active lifestyles. Available in chocolate and vanilla, it is sold at major U.S. retailers like Walmart and Amazon. Abbott aims to simplify muscle nutrition by combining key ingredients in one daily serving, supporting both short-term exercise recovery and long-term muscle preservation.

As of Oct 07, 2026 20:12 WIB, Abbott Laboratories (ABT) shares are trading at USD 98.75 on Pluang, showing a modest 1-day gain of 0.59%. The stock maintains a strong market presence with a market cap of $169.85 billion and an enterprise value of $196.86 billion. Investor interest remains high with 82% of Pluang orders being buys, reflecting confidence in Abbott's health sector innovations like the new Ensure Max Protein 3-in-1 Muscle Support.

More News (ABT)

Abbott lowers 2026 outlook amid demand headwinds; spin-off may boost growth and margins.

Abbott lowers 2026 outlook amid demand headwinds; spin-off may boost growth and margins.

Abbott Laboratories has lowered its full-year 2026 guidance following weaker-than-expected demand in its EP/CGM segments during the fourth quarter. The company plans a nutrition business spin-off, which could unlock growth in its MedTech, Diagnostic,...

Company Fundamentals
Neutral
7 hours ago
Medtronic raises dividend by 1.4%, continuing 49-year streak but lags peers Abbott and J&J.

Medtronic raises dividend by 1.4%, continuing 49-year streak but lags peers Abbott and J&J.

Medtronic increased its quarterly dividend to $0.72 per share, marking a 1.4% raise and extending its dividend increase streak to 49 years. While this steady growth ensures a reliable 2.95% yield, it trails behind faster-growing peers like Abbott and...

Bullish
9 hours ago
Abbott Laboratories stays a Buy with strong device growth and Nutrition spin-off boosting margins and growth.

Abbott Laboratories stays a Buy with strong device growth and Nutrition spin-off boosting margins and growth.

Abbott Laboratories is rated a Buy due to strong growth in its medical devices and diagnostics segments, which now make up 70% of its revenue. The company’s recent acquisition of Exact Sciences has accelerated diagnostics growth. Abbott plans to spin...

Analyst Insights
Bullish
1 day ago
New Abbott test shows 10.6-fold higher risk of colorectal cancer recurrence post-surgery via sensitive DNA detection.

New Abbott test shows 10.6-fold higher risk of colorectal cancer recurrence post-surgery via sensitive DNA detection.

Abbott announced results from the Beta-CORRECT study showing its Oncodetect test, using whole-genome sequencing, improves detection of molecular residual disease (MRD) in colorectal cancer patients after surgery. The test showed a 30% higher sensitiv...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App